Welcome to our dedicated page for Applied Dna Scie SEC filings (Ticker: APDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BNB Plus Corp. filings document the former Applied DNA Sciences, Inc. issuer's corporate transition, including its name change, BNBX trading symbol, Nasdaq-listed common stock, governance changes, restructuring actions, and capital-raising activity. Recent 8-K filings cover charter amendments, board leadership changes, exit and disposal costs, private placements, warrants, and at-the-market offering arrangements.
Registration statements and proxy materials describe the company's common stock, warrant securities, shelf registration use, shareholder voting matters, authorized-share proposals, and risk and capital-structure disclosures. Periodic reporting also records the company's LineaRx-focused synthetic DNA and mRNA manufacturing operations, discontinued business activities, operating results, and segment presentation.
Applied DNA Sciences, Inc. implemented significant corporate and capital-structure actions in fiscal 2025 while restructuring operations to focus on Therapeutic DNA Production Services. The company completed two reverse stock splits (board-authorized 1-for-50 then 1-for-15, effective June 2, 2025) that adjusted warrant exercise prices and share counts. Since January 2025 the company has reduced headcount by 39%, expects a projected 31% reduction in payroll expenses versus fiscal 2024, and recorded approximately $305,000 and an additional $300,000 in one-time charges related to workforce reductions and ceasing ADCL operations; ADCL is accounted for as discontinued operations.
Revenue and receivables show high customer concentration (e.g., 26%, 23%, 12% in key segments; three customers represented 82% of accounts receivable at June 30, 2025). The company completed an October registered/direct offering with instruments priced at $240.00 (pre-funded warrants exercised during the period) and agreed to placement agent fees of 6% plus warrants. Lease and cash commitments include a $750,000 standby letter of credit and rent expense of $157,320 and $498,416 for the three- and nine-month periods ended June 30, 2025.